Pliant Therapeutics appoints Flavia Borellini, Robert Iannone to board

Pliant Therapeutics has appointed Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its board of directors. Borellini brings oncology drug development leadership from Acerta Pharma and AstraZeneca, while Iannone contributes clinical development and regulatory experience from Jazz Pharmaceuticals and Immunomedics.

Pliant Therapeutics appointed Flavia Borellini, Ph.D. to its board, adding oncology drug development leadership from Acerta Pharma and AstraZeneca. * Borellini previously led development of Calquence at Acerta Pharma, earlier ran AstraZeneca’s hematology franchise, previously held senior roles at Genentech. * Robert Iannone, M.D., M.S.C.E. also joined the board, bringing clinical development and regulatory experience from Jazz Pharmaceuticals and Immunomedics. * Iannone previously led immuno-oncology development at AstraZeneca, earlier ran oncology clinical development at Merck, including work on KEYTRUDA. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Pliant Therapeutics appointed Flavia Borellini, Ph.D. to its board, adding oncology drug development leadership from Acerta Pharma and AstraZeneca. * Borellini previously led development of Calquence at Acerta Pharma, earlier ran AstraZeneca’s hematology franchise, previously held senior roles at Genentech. * Robert Iannone, M.D., M.S.C.E. also joined the board, bringing clinical development and regulatory experience from Jazz Pharmaceuticals and Immunomedics. * Iannone previously led immuno-oncology development at AstraZeneca, earlier ran oncology clinical development at Merck, including work on KEYTRUDA. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here